2-({4-[(7-chloroquinolin-4-yl)amino]pentyl}(ethyl)amino)ethan-1-ol

• ChemBase编号: 1388
• 分子式: C18H26ClN3O
• 平均质量: 335.87154
• 单一同位素质量: 335.17644015
• SMILES: Clc1cc2nccc(NC(CCCN(CCO)CC)C)c2cc1
• Canonical SMILES: OCCN(CCCC(Nc1ccnc2c1ccc(c2)Cl)C)CC
• InChI: InChI=1S/C18H26ClN3O/c1-3-22(11-12-23)10-4-5-14(2)21-17-8-9-20-18-13-15(19)6-7-16(17)18/h6-9,13-14,23H,3-5,10-12H2,1-2H3,(H,20,21)
• InChIKey: XXSMGPRMXLTPCZ-UHFFFAOYSA-N

名称和登记号

名称

• IUPAC标准名: 2-({4-[(7-chloroquinolin-4-yl)amino]pentyl}(ethyl)amino)ethan-1-ol
• IUPAC传统名: hydroxychloroquine
• 商标名: Ercoquin; Quensyl; Plaquenil
• 别名: 2-((4-((7-Chloro-4-quinolyl)amino)pentyl)ethylamino)ethanol; Gen-Hydroxychloroquine 200mg Tablets; HCQ; Hidroxicloroquina [inn-spanish]; Hydroxychloroguine; Hydroxychloroquine sulfate; Hydroxychloroquinum [inn-latin]; Idrossiclorochina [dcit]; Oxichlorochinum; Oxichloroquine; Oxychlorochin; Oxychloroquine; Hydroxychloroquine

登记号

• CAS号: 118-42-3
• PubChem SID: 160964848; 46508459
• PubChem CID: 3652
• ATC码: P01BA02
• CHEMBL: 1535
• Chemspider ID: 3526
• DrugBank ID: DB01611
• KEGG ID: D08050
• 美国药典/FDA物质标识码: 4QWG6N8QKH
• 维基百科标题: Hydroxychloroquine
• Medline Plus: a601240

理论计算性质

JChem

• Acid pKa: 15.59329
• 质子受体: 4
• 质子供体: 2
• LogD (pH = 5.5): -1.7593226
• LogD (pH = 7.4): 0.3267855
• Log P: 2.8869712
• 摩尔折射率: 97.9667 cm^3
• 极化性: 38.672028 Å^3
• 极化表面积: 48.39 Å^2
• 可自由旋转的化学键: 9
• 里宾斯基五规则: true

ALOGPS 2.1

• Log P: 3.87
• LOG S: -4.11
• 溶解度: 2.61e-02 g/l

分子性质

药理学性质

• 给药途径: Oral
• 排泄: Renal
• 半衰期: 1–2 months
• 法定药品分级: POM (UK), ?-only (U.S.)
• 妊娠期药物分类: D (Au), C (U.S.)

详细说明

DrugBank - DB01611

• Drug Groups: approved
• Description: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites.
• Indication: For the suppressive treatment and treatment of acute attacks of malaria due to Plasmodium vivax, P. malariae, P. ovale, and susceptible strains of P. falciparum. It is also indicated for the treatment of discoid and systemic lupus erythematosus, and rheumatoid arthritis.
• Pharmacology: Hydroxychloroquine possesses antimalarial properties and also exerts a beneficial effect in lupus erythematosus (chronic discoid or systemic) and acute or chronic rheumatoid arthritis. The precise mechanism of action is not known.
• Toxicity: Symptoms of overdose include headache, drowsiness, visual disturbances, cardiovascular collapse, and convulsions, followed by sudden and early respiratory and cardiac arrest. The electrocardiogram may reveal atrial standstill, nodal rhythm, prolonged intraventricular conduction time, and progressive bradycardia leading to ventricular fibrillation and/or arrest.
• Affected Organisms: Plasmodium
• Biotransformation: Partially hepatic, to active de-ethylated metabolites.
• Absorption: Very rapidly and completely absorbed following oral administration.
• Half Life: Terminal elimination half-life In blood is approximately 50 days. In plasma it is approximately 32 days.
• Protein Binding: Approximately 45%.
• External Links: Wikipedia; RxList; Drugs.com